作者
Arielle Elkrief,Meagan Montesion,Smruthy Sivakumar,Caryn Hale,Anita S. Bowman,Ayyüce Begüm Bektaş,Martina Bradić,Wenfei Kang,Eric Chan,Pooja Gogia,Katia Manova–Todorova,Douglas A. Mata,Jacklynn V. Egger,Hira Rizvi,Nicolas D. Socci,Daniel W. Kelly,Eric Rosiek,Fanli Meng,Grittney Tam,Ning Fan,Alexander Drilon,Helena A. Yu,Gregory J. Riely,Natasha Rekhtman,Álvaro Quintanal-Villalonga,Snjezana Doğan,Umesh Bhanot,Mithat Gönen,Brian Houck‐Loomis,Matthew D. Hellmann,Adam J. Schoenfeld,Marc Ladanyi,Charles M. Rudin,Chad Vanderbilt
摘要
PURPOSE The impact of the intratumoral microbiome on immune checkpoint inhibitor (ICI) efficacy in patients with non–small-cell lung cancer (NSCLC) is unknown. Preclinically, intratumoral Escherichia is associated with a proinflammatory tumor microenvironment and decreased metastases. We sought to determine whether intratumoral Escherichia is associated with outcome to ICI in patients with NSCLC. PATIENTS AND METHODS We examined the intratumoral microbiome in 958 patients with advanced NSCLC treated with ICI by querying unmapped next-generation sequencing reads against a bacterial genome database. Putative environmental contaminants were filtered using no-template controls (n = 2,378). The impact of intratumoral Escherichia detection on overall survival (OS) was assessed using univariable and multivariable analyses. The findings were further validated in an external independent cohort of 772 patients. Escherichia fluorescence in situ hybridization (FISH) and transcriptomic profiling were performed. RESULTS In the discovery cohort, read mapping to intratumoral Escherichia was associated with significantly longer OS (16 v 11 months; hazard ratio, 0.73 [95% CI, 0.59 to 0.92]; P = .0065) in patients treated with single-agent ICI, but not combination chemoimmunotherapy. The association with OS in the single-agent ICI cohort remained statistically significant in multivariable analysis adjusting for prognostic features including PD-L1 expression ( P = .023). Analysis of an external validation cohort confirmed the association with improved OS in univariable and multivariable analyses of patients treated with single-agent ICI, and not in patients treated with chemoimmunotherapy. Escherichia localization within tumor cells was supported by coregistration of FISH staining and serial hematoxylin and eosin sections. Transcriptomic analysis correlated Escherichia-positive samples with expression signatures of immune cell infiltration. CONCLUSION Read mapping to potential intratumoral Escherichia was associated with survival to single-agent ICI in two independent cohorts of patients with NSCLC.